Incyte, Eli Lilly deal

Incyte granted Eli Lilly exclusive, worldwide rights to develop and commercialize Incyte's INCB28050 and follow-on compounds for inflammatory and autoimmune diseases. The Janus kinase-1 (JAK-1) and JAK-2 inhibitor is in Phase II testing to treat rheumatoid arthritis. Incyte will receive $90 million up front and is eligible for up to $665 million in milestones, plus tiered, double-digit royalties up to 20%. ...